New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 9, 2014
10:01 EDTM, WSM, INSM, ANGI, LLL, DHI, DAN, CACI, FRX, AET, HAL, STI, MPW, JCP, AZN, VAL, RVBD, MCD, DD, ALB, TS, PSA, JNJ, DOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Aetna (AET) upgraded to Outperform from Neutral at Credit Suisse... Albemarle (ALB) upgraded to Buy from Neutral at BofA/Merrill... AstraZeneca (AZN) upgraded to Hold from Underperform at Jefferies... Dominion (D) upgraded to Buy from Neutral at UBS... DuPont (DD) upgraded to Buy from Neutral at BofA/Merrill... J.C. Penney (JCP) upgraded to Overweight from Neutral at Piper Jaffray... Johnson & Johnson (JNJ) upgraded to Buy from Hold at Jefferies... McDonald's (MCD) upgraded to Overweight from Equal Weight at Morgan Stanley... Medical Properties Trust (MPW) upgraded to Buy from Hold at Jefferies... Public Storage (PSA) upgraded to Buy from Hold at Jefferies... Riverbed (RVBD) upgraded to Hold from Sell at Deutsche Bank... SunTrust (STI) upgraded to Neutral from Underperform at BofA/Merrill... Valspar (VAL) upgraded to Outperform from Neutral at RW Baird... Tenaris (TS) upgraded to Outperform from Sector Perform at Howard Weil... Halliburton (HAL) upgraded to Outperform from Sector Perform at Howard Weil... Forest Labs (FRX) upgraded to Buy from Neutral at Buckingham... D.R. Horton (DHI) upgraded to Buy from Neutral at MKM Partners... Insmed (INSM) upgraded at JMP Securities... CACI International (CACI) upgraded to Overweight from Neutral at JPMorgan... L-3 Communications (LLL) upgraded to Neutral from Underweight at JPMorgan... H&R Block (HRB) upgraded to Buy from Neutral at BTIG... Williams-Sonoma (WSM) upgraded to Buy from Hold at Argus... Dana Holding (DAN) upgraded to Buy from Neutral at Goldman... Angie's List (ANGI) upgraded at Raymond James... Macy's (M) upgraded to Outperform from Market Perform at BMO Capital.
News For AET;ALB;AZN;D;DD;JCP;JNJ;MCD;MPW;PSA;RVBD;STI;TS;VAL;HAL;FRX;DHI;INSM;CACI;LLL;WSM;DAN;ANGI;M From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>
January 15, 2015
07:37 EDTDHID.R. Horton initiated with an Equal Weight at Morgan Stanley
Subscribe for More Information
07:06 EDTJNJJohnson & Johnson downgraded at Goldman
Subscribe for More Information
06:44 EDTJNJJohnson & Johnson downgraded to Sell from Neutral at Goldman
06:36 EDTMCDMcDonald's experimenting with new concepts in Australia, Reuters says
Subscribe for More Information
06:15 EDTDHID.R. Horton downgraded to Neutral from Buy at UBS
UBS downgraded D.R. Horton due to valuation. Price target remains $26.
January 14, 2015
16:08 EDTVALValspar initiated with a Neutral at Piper Jaffray
Subscribe for More Information
16:05 EDTDHISanders Capital reports 5.58% passive stake in D.R. Horton
10:00 EDTVALOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: ACE Limited (ACE) downgraded to Neutral from Outperform at Macquarie... AXIS Capital (AXS) downgraded to Neutral from Outperform at Macquarie... Allstate (ALL) downgraded to Underperform from Neutral at Macquarie... Altera (ALTR) downgraded to Neutral from Overweight at JPMorgan... American Midstream Partners (AMID) downgraded to Neutral from Buy at BofA/Merrill... Argo Group (AGII) downgraded to Underperform from Neutral at Macquarie... Aspen Insurance (AHL) downgraded to Underperform from Neutral at Macquarie... Beneficial Bancorp (BNCL) downgraded to Neutral at Boenning & Scattergood... CDW Corporation (CDW) downgraded to Neutral from Buy at Goldman... CHC Group (HELI) downgraded at Raymond James... CIRCOR (CIR) downgraded to Hold from Buy at Stifel... Chesapeake (CHK) downgraded to Underweight from Equal Weight at Barclays... Commerzbank (CRZBY) downgraded to Sell from Neutral at Goldman... Continental Resources (CLR) downgraded to Equal Weight from Overweight at Barclays... Corporate Office Properties (OFC) downgraded to Market Perform at Wells Fargo... Credit Suisse (CS) downgraded to Neutral from Overweight at HSBC... Datawatch (DWCH) downgraded to Hold at Canaccord... Devon Energy (DVN) downgraded to Equal Weight from Overweight at Barclays... Dollar Tree (DLTR) downgraded to Neutral from Buy at Northcoast... Douglas Emmett (DEI) downgraded to Neutral from Buy at Mizuho... Dresser-Rand (DRC) downgraded to Underperform from Market Perform at Raymond James... Enable Midstream (ENBL) downgraded to Underperform from Neutral at BofA/Merrill... F5 Networks (FFIV) downgraded to Equal Weight from Overweight at Barclays... First Majestic (AG) downgraded to Sector Perform from Outperform at Scotia Capital... Foot Locker (FL) downgraded to Sell from Neutral at Goldman... Franklin Resources (BEN) downgraded to Neutral from Buy at Goldman... HCP (HCP) downgraded to Market Perform from Outperform at Wells Fargo... Halcon Resources (HK) downgraded to Underweight from Equal Weight at Barclays... Insulet (PODD) downgraded at Sterne Agee... J.B. Hunt (JBHT) downgraded to Market Perform from Outperform at Avondale... JPMorgan (JPM) downgraded to Underweight from Neutral at HSBC... KB Home (KBH) downgraded to Neutral from Outperform at Credit Suisse... Kosmos (KOS) downgraded to Equal Weight from Overweight at Barclays... Marathon Oil (MRO) downgraded to Equal Weight from Overweight at Barclays... Medley Management (MDLY) downgraded to Market Perform at Keefe Bruyette... MoneyGram (MGI) downgraded to Underperform from Neutral at BofA/Merrill... NPS Pharmaceuticals (NPSP) downgraded to Neutral from Overweight at JPMorgan... National Grid (NGG) downgraded to Underperform from Neutral at Credit Suisse... Navigators (NAVG) downgraded to Underperform from Neutral at Macquarie... Pioneer Energy (PES) downgraded at Raymond James... RSP Permian (RSPP) downgraded to Equal Weight from Overweight at Barclays... Rambus (RMBS) downgraded to Neutral from Overweight at JPMorgan... Realty Income (O) downgraded to Market Perform from Outperform at Wells Fargo... Red Hat (RHT) downgraded to Sell from Neutral at Goldman... Resolute Energy (REN) downgraded to Underweight from Equal Weight at Barclays... Ross Stores (ROST) downgraded to Neutral at UBS... SandRidge Energy (SD) downgraded to Underweight from Equal Weight at Barclays... Tech Data (TECD) downgraded to Sell from Neutral at Goldman... Teekay Offshore Partners (TOO) downgraded to Neutral from Buy at BofA/Merrill... Travelers (TRV) downgraded to Underperform from Neutral at Macquarie... TrueCar (TRUE) downgraded to Market Perform at Cowen... Valspar (VAL) downgraded to Neutral from Outperform at RW Baird... Verizon (VZ) downgraded at Evercore ISI... Viacom (VIAB) downgraded to Sell from Buy at Citigroup... W. R. Berkley (WRB) downgraded to Underperform from Neutral at Macquarie... Waddell & Reed (WDR) downgraded to Neutral from Buy at Goldman... Western Union (WU) downgraded to Underperform from Neutral at BofA/Merrill... Whiting Petroleum (WLL) downgraded to Equal Weight from Overweight at Barclays... Whole Foods (WFM) downgraded to Hold from Buy at Argus... Xilinx (XLNX) downgraded to Neutral from Overweight at JPMorgan... iRobot (IRBT) downgraded to Underweight from Neutral at JPMorgan.
09:54 EDTMCDMcDonald's slips after Ackman says rumored investment 'unlikely'
Subscribe for More Information
09:51 EDTJNJJohnson & Johnson unit says study shows consistent Xarelto safety
Johnson & Johnson unit Janssen announced that a new post-marketing study evaluating the safety of once-daily Xarelto shows, in patients with non-valvular atrial fibrillation, rates and patterns of major bleeding in routine clinical practice are generally consistent with those observed in Phase 3 clinical trials used to approve the medicine for this indication. The fifteen-month results, published today in Clinical Cardiology, represent initial findings from an ongoing, five-year, observational study of patients using Xarelto daily over the course of their lives.
09:46 EDTMCDAckman says 'unlikely' to invest in McDonald's, Bloomberg reports
Subscribe for More Information
08:51 EDTVALValspar downgraded to Neutral at RW Baird
Subscribe for More Information
07:42 EDTPSAUBS to hold a summit
Subscribe for More Information
07:37 EDTAZN, INSMJPMorgan to hold a conference
Subscribe for More Information
07:25 EDTLLLL-3 Communications coverage resumed with a Hold at Stifel
Subscribe for More Information
07:06 EDTDHIKB Home margin issues company specific, says Deutsche Bank
Subscribe for More Information
07:03 EDTAZNAstraZeneca says Pegasus-TIMI 54 study met primary efficacy endpoint
AstraZeneca announced that the PEGASUS-TIMI 54 study, a large scale outcomes trial involving over 21,000 patients, successfully met its primary efficacy endpoint. The study assessed BRILINTA tablets at either 60mg twice daily or 90mg twice daily plus low-dose aspirin for the secondary prevention of atherothrombotic events in patients who had experienced a heart attack one to three years prior to study start. The primary efficacy endpoint was a composite of cardiovascular death, myocardial infarction or stroke. Preliminary analysis did not reveal any unexpected safety issues. Full evaluation of the data is ongoing. The PEGASUS-TIMI 54 study investigated two different doses of ticagrelor on a background of low dose aspirin versus placebo plus low dose aspirin, in patients aged 50 and older with a history of heart attack and one additional CV risk factor. The study was designed to better understand the management of patients more than 12 months after their heart attack, who remain at high risk for major thrombotic events. Complete results from the PEGASUS-TIMI 54 study will be submitted to a scientific meeting in 2015 and pending further analysis, AstraZeneca plans to file this data with regulatory health authorities. The PEGASUS-TIMI 54 study is part of AstraZeneca’s PARTHENON program. The PLATO study, involving over 18,000 ACS patients, was the first study in the program and is the basis on which ticagrelor has been approved in over 100 countries and included in 12 major ACS treatment guidelines globally. Further ongoing PARTHENON studies are investigating ticagrelor for the prevention of cardiovascular events in patients with peripheral arterial disease, ischaemic stroke or transient ischaemic attack, and in patients with diabetes and coronary atherosclerosis. BRILINTA is not approved for secondary prevention of atherothrombotic events in patients with a history of heart attack beyond one year or for the prevention of cardiovascular events in patients with PAD, stroke, diabetes or atherosclerosis.
07:03 EDTAZNAstraZeneca says Pegasus-TIMI 54 study met primary efficacy endpoint
06:55 EDTMCDMcDonald's Japan finds plant doesn't use plastic found in McNugget, Reuters says
Subscribe for More Information
06:50 EDTVALValspar downgraded to Neutral from Outperform at RW Baird
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use